ACT 128800

Known as: ACT-128800, ACT128800 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
0120102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis… (More)
  • figure 1
  • figure 2
  • table 1
  • table 3
Is this relevant?
Review
2015
Review
2015
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple… (More)
Is this relevant?
2014
2014
Ponesimod (ACT-128800), a reversible, orally active, selective S1P1 receptor modulator, prevents the egress of lymphocytes from… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2010
2010
Sphingosine-1-phosphate (S1P) is a widespread lysophospholipid which displays a wealth of biological effects. Extracellular S1P… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?